Background Oral calcium and calcitriol are often prescribed after total thyroidectomy to avoid biochemical and/ or symptomatic hypocalcemia. We aimed to identify independent perioperative factors that correlated with the duration of calcium and/or calcitriol supplementation after total thyroidectomy. Methods Of 271 eligible patients, 48 (17.7 %) required calcium and/or calcitriol supplements on discharge. Patients were gradually weaned from the supplementation by one surgeon according to a biweekly algorithm based on serum calcium (Ca). Duration of supplementation was calculated from the date of operation to the date of ceasing all supplementation without biochemical hypocalcemia (i.e., serum adjusted Ca C8.44 mg/dL). The Cox regression analysis was performed to identify independent perioperative factors for duration of supplementation. The best cutoff value for these independent factors was determined by the receiver characteristic curve. Results In the multivariate analysis, parathyroid hormone (PTH) at skin closure (PTH-SC) (RR 1.742, 95 % CI 1.080-2.810) and on postoperative day 1 adjusted Ca (Ca-D1) (RR 77.526, 95 % CI 3.600-1669.57) were the only two independent determinants for shorter duration before ceasing all supplementation. The best cut-off values in predicting supplementation C6 months for PTH-SC and Ca-D1 were 7.08 pg/mL (sensitivity = 100 %, specificity = 60.5 %, PPV = 40.0 % and NPV = 100 %) and 7.88 mg/dL (sensitivity = 90.0 %, specificity = 55.3 %, PPV = 34.6 % and NPV = 95.5 %), respectively. Conclusions Both PTH-SC and Ca-D1 were independently associated with the duration of supplementation after total thyroidectomy. Almost all patients with PTH-SC C7.08 pg/mL or Ca-D1 C7.88 mg/dL did not require supplementation C6 months whereas about one third of patients with PTH-SC \7.08 pg/mL or Ca-D1 \7.88 mg/ dL required supplementation C6 months.
Introduction
Postoperative hypoparathyroidism leading to hypocalcemia is one of the most frequent morbidities following total thyroidectomy, with an incidence ranging between 3 and 40 % [1] . However, because potentially life-threatening hypocalcemia does not usually develop until 24 to 48 h after surgery, hypoparathyroidism may delay early hospital discharge [2] [3] [4] . To safely manage postoperative hypoparathyroidism/hypocalcemia without unnecessarily prolonging hospital stay, two different approaches have often been adopted, namely routine calcium and/or calcitriol supplementation or selective supplementation, based on postoperative intact parathyroid hormone (PTH) values [2] [3] [4] . Some researchers have advocated the latter approach because PTH testing within a few hours of surgery could accurately predict clinically relevant hypocalcemia in the immediate postoperative period [5] [6] [7] [8] [9] [10] . However, few studies have focused on its predictive value in persistent/ long-term hypocalcemia [11] [12] [13] [14] . Wang et al. [14] evaluated the predictive value of postoperative day (POD) 1 PTH (PTH-D1) on the need for calcitriol supplementation [1 month and found that none of the 78 patients with PTH-D1 C5 pg/mL required calcium and calcitriol supplementation lasting [1 month. The implication is that patients with a normal to near-normal postoperative PTH level would have a shorter duration or greater chance of ceasing all supplementation than those with low to undetectable initial PTH. This information is relevant to clinicians because the process of weaning off supplementation in patients with hypoparathyroidism often entails multiple clinic visits and blood tests [11] [12] [13] [14] . Therefore, knowing which perioperative factors could predict the duration of supplementation could potentially reduce the number/frequency of clinic visits and overall costs. However, to our knowledge, few studies have specifically examined the association between perioperative biochemical factors and duration or chance of ceasing calcium and/or calcitriol supplementation after total thyroidectomy [9] [10] [11] [12] [13] [14] . We hypothesized that the perioperative PTH and adjusted calcium (Ca) (i.e., the severity of immediate postoperative hypoparathyroidism) might be associated with the duration and the chance of weaning off calcium and/or calcitriol supplementation after total thyroidectomy.
Methods and patients
The present study protocol was approved by the local institutional review board. From October 2010 to December 2011, 316 consecutive patients underwent a total or completion-total thyroidectomy. All had PTH at skin closure (PTH-SC) and PTH-D1 taken. To minimize other confounders, those with concomitant central selective neck dissection (n = 15), active bone disease (evident by preoperative bone alkaline phosphatase [150 IU/L) (n = 3), incomplete/missing postoperative PTH values (n = 7), or completion total thyroidectomy (n = 20) were excluded. Therefore, 271 patients were eligible for analysis.
Postoperative calcium monitoring, supplementation, and follow-up protocol All postoperative patients were monitored for hypocalcemia. Calcium was checked within 4 h after operation, on the following morning (i.e., on POD 1) (Ca-D1), and every 8-10 h until stabilized. Clinically significant hypocalcemia was defined by the presence of hypocalcemic symptoms and/or a postoperative serum Ca drop to \7.60 mg/dL (normal range 8.44-10.20 mg/dL). Those with clinically significant hypocalcemia were initially given 2,500 mg Os Cal tablets (as calcium supplements) and were further given calcitriol 0.50 lg twice daily if[2,500 mg of Os Cal tablets alone failed to maintain normocalcemia. The person prescribing the oral calcium and/or calcitriol supplementation was unaware of the PTH results. Patients were discharged from the hospital and followed up for 7-10 days after surgery. Their serum Ca level was checked at discharge. Figure 1 shows the algorithm for weaning patients off calcium and/or calcitriol supplementation after discharge. To avoid individual variability, one surgeon (B.H.L.) was responsible for weaning patients off supplementation. As a general rule, weaning from calcitriol supplementation was accomplished in a stepwise manner before weaning from the calcium supplementation. To avoid the problem of premature weaning, a serum Ca test was repeated a week later. Patients on calcium and/or calcitriol supplementation were checked every 2-3 weeks until they were weaned from all supplementation. The same follow-up protocol was applied to all patients irrespective of their postoperative PTH levels. Patients no longer on supplementation were followed monthly for 6-12 months. All postoperative patients were followed for 2 years before being discharged to their primary care physicians.
The duration of supplementation (in days) was calculated from the date of primary operation to the date when the patient had been weaned from all supplementation and had biochemical normocalcemia (i.e., Ca C8.44 mg/dL) (to convert mg/dL to mmol/L, multiply by 0.25). To ensure that those not requiring calcium and/or calcitriol supplementation had really not taken any supplementation (such as those who might have taken calcium supplementation from other physicians for other indications), a careful manual search of all patients' medication status in the territory-wide Clinical Management System (CMS) was performed. The CMS is a computerized database that captures all medication entries for all patients in our locality [15] .
Surgical technique
Surgical techniques had been previously described [16] . Any devascularized parathyroid glands were immediately minced and auto-implanted to the ipsilateral sternocleidomastoid muscle. All data were prospectively recorded.
Laboratory methods
Calcium and phosphate levels were measured in the hospital laboratory by standard methods with the Roche Diagnostics Modular Analytic system (Roche Diagnostics, Indianapolis, IN). The PTH level was measured by the Access 2 Immunoassay System (Beckman Coulter, Brea, CA), and the inter-and intra-assay coefficients of variability (CVs) were 5.8 and 4.5 %, respectively. The normal range for PTH was 11.3-53.8 pg/mL (to convert pg/mL to pmol/L, multiply by 0.106). Serum 25-hydroxyvitamin D was measured by using the electrochemiluminescence immunoassay (Elecsys Vitamin D Total assay), and the inter-and intra-assay CVs were 6.2 and 4.8 %, respectively. The measuring range was 3.00-70.0 ng/mL (to convert ng/mL to nmol/L, multiply by 2.496).
Statistics
Cox proportional hazards regression was used to evaluate the association between potential perioperative parameters and duration of supplementation (or chance of weaning off supplementation) in both univariate and multivariate analyses. Only significant variables in the univariate analysis were entered into the multivariate analysis. To improve clinical utility of independent continuous variables, the receiver operating characteristic (ROC) curve were performed to calculate the best cut-off value for predicting duration of supplementation C6 months. The reason for choosing 6 months was because it is often considered a cut-off for temporary and permanent hypoparathyroidism. Test sensitivity = true positive/(true positive?false negative); test specificity = true negative/ (false positive?true negative); positive predictive value (PPV) = true positive/(true positive?false positive); negative predictive value (NPV) = True negative/(false negative?true negative). All statistical analyses were conducted using SPSS version 18.0 (SPSS, Inc., Chicago, IL). p \ 0.05 was considered statistically significant. Table 1 shows the patient baseline characteristics and follow-up data. A total of 271 patients underwent a total Table 2 shows the univariate analysis for duration of stopping calcium and/or calcitriol supplementation. PTH-SC C7.08 pg/mL (p = 0.001), PTH-D1 C9.43 pg/mL (p = 0.003) and Ca-D1 C7.88 mg/dL (p = 0.001) were significant factors for shorter duration of supplementation. When entered as continuous variables, the PTH-SC (RR 1.44, 95 % CI 1.15-1.81; p = 0.002), PTH-D1 (RR 1.34, 95 % CI 1.10-1.62; p = 0.003), and Ca-D1 (RR 69.1, 95 % CI 4.54-1054.87; p = 0.002) were significant factors associated with the duration of supplementation. Table 3 shows the multivariate analysis for duration of stopping calcium and/or calcitriol supplementation. When entered as continuous variables, PTH-SC (RR 1.742, 95 % CI 1.080-2.810; p = 0.023) and Ca-D1 (RR 77.526, 95 % CI 3.600-1669.57; p = 0.005) were the two independent factors for duration of supplementation. When the 10 patients on supplementation C6 months were excluded, PTH-SC and Ca-D1 remained significant (RR 1.245, 95 % CI 1.001-1.548; p = 0.049 and RR 30.886, 95 % CI 1.792-532.446; p = 0.018, respectively).
Results
Using the ROC, the best cut-off values in predicting supplementation C6 months for PTH-SC and Ca-D1 were 7.08 pg/mL (sensitivity = 100 %, specificity = 60.5 %, PPV = 40.0 % and NPV = 100 %) and 7.88 mg/dL (sensitivity = 90.0 %, specificity = 55.3 %, PPV = 34.6 % and NPV = 95.5 %), respectively. Table 4 is a summary table between PTH-SC\7.08 and C7.08 pg/mL and those requiring supplements \6 months, C6 months and no supplements. Those with PTH-SC C7.08 pg/mL, the median (range) duration of supplementation was 60 (7-126) days, whereas for those with PTH-SC \7.08 pg/mL, the duration was 140 (7-598) days. Of the 10 patients on supplementation C6 months, 3 patients still required supplementation at last follow-up (511, 556, and 598 days, respectively), while the other 7 patients stopped supplementation after 231, 283, 297, 204, 339, 350, and Table 5 is a summary table comparing Ca-D1\7.88 and C7.88 mg/dL in patients those requiring supplements \6 months, C6 months and no supplements. In those with Ca-D1 C7.88 mg/dL, the median (range) duration of supplementation was 61 (7-556) days, whereas for those with Ca-D1 \7.88 mg/dL, the duration was 122 (8-598) days. Only one patient with Ca-D1 C7.88 mg/dL required supplementation C6 months. Table 6 shows use of a combination of PTH-SC and Ca-D1 in predicting the need for supplementation for \6 months and C6 months. Nine of 17 patients with PTH-SC \7.08 pg/mL and Ca-D1 \7.88 mg/dL required supplementation C6 months. By combining both PTH-SC and Ca-D1, the PPV increased to 9/17 (52.9 %) while the sensitivity was 14/14 (100 %). No patient with a combined PTH-SC C7.08 pg/mL and Ca-D1 C7.88 mg/dL required supplementation C6 months. The median duration for this subgroup was 36 (7-126) days. By using the formula [0.554 9 (1.740 9 PTH-SC)] ? [4.350 9 (77.523 9 Ca-D1)] derived from the Cox regression model in the multivariate analysis, the AUC for combined PTH-SC and Ca-D1 was slightly higher than the AUC for PTH-SC and Ca-D1 alone (0.955 vs. 0.943 and 0.950, respectively).
Discussion
The proportion of patients requiring calcium and/or calcitriol supplementation to prevent biochemical and/or symptomatic hypocalcemia after total thyroidectomy tends to vary and is dependent on a multitude of factors including preoperative thyroid function, vitamin D level, surgical indications, extent of surgery, underlying metabolic bone disease, and individual surgeon's threshold for supplementation [1, 15, 17] . However, even when selective supplementation (as opposed to routine) is adopted, up to 40 % of patients might require some form of supplementation on hospital discharge [1] . Our study aimed to examine what perioperative factors or indicators were associated with the duration of ceasing all supplementation. By knowing these factors, perhaps, the process of weaning off supplementation could become more precise [8, 11-14, 17, 18] . Although previous studies have examined this issue [11] [12] [13] [14] , they did not specifically evaluate the extent of Ca-D1 C7.88 mg/mL (n = 22) 1 (FN) 21 (TN) 221 Table 6 A summary table comparing PTH at skin closure (PTH-SC) and postoperative day-1 adjusted calcium (Ca-D1) in patients on supplements \6 months and C6 months Supplementation for [6 months (n = 10) Supplementation for B6 months (n = 38) PTH-SC \7.08 pg/mL and Ca-D1 \7.88 mg/dL (n = 17) 9 8
PTH-SC C7.08 pg/mL and Ca-D1 \7.88 mg/dL (n = 9) 0 9
PTH-SC \7.08 pg/mL and Ca-D1 C7.88 mg/dL (n = 8) 1 7
PTH-SC C7.08 pg/mL and Ca-D1 C7.88 mg/dL (n = 14) 0 14 perioperative biochemical factors in predicting the duration of supplementation. Furthermore, it was unclear if their patients were being weaned off the supplementation with a standardized and intensive follow-up protocol. In our study, 15 patients with concomitant central neck dissection and 3 patients with active bone disease were excluded from analysis because such patients often require a prolonged period of supplementation irrespective of their residual parathyroid function [11] . In the univariate analysis, PTH-SC, PTH-D1, and Ca-D1 were significant factors for shorter duration of supplementation. Based our results, relative to PTH-SC \7.08 pg/mL, those with PTH C7.08 pg/mL had 3.59 times shorter duration of needing supplementation. Similarly, those with PTH-D1 C9.43 pg/ mL and Ca-D1 C7.88 mg/dL had 2.84 and 3.20 times shorter duration of supplementation, respectively. However, because PTH and Ca were closely inter-related, a multivariate analysis was performed. In the multivariate analysis, both PTH-SC and Ca-D1 turned out as independent predictors for duration of supplementation and remained significant even when the 10 patients on supplementation C6 months (i.e., those with possible permanent hypoparathyroidism) were excluded. Relative to PTH-SC \7.08 pg/mL, PTH-SC C7.08 pg/mL had 2.87 times shorter duration of supplementation while relative to Ca-D1 \7.88 mg/dL, Ca-D1 C7.88 mg/dL had 2.69 times shorter duration of supplementation. These findings concurred with our later findings that the median duration of supplementation for PTH \7.08 and C7.08 pg/mL were 140 and 62 days, respectively. Similarly, the median duration for Ca-D1 \7.88 and C7.88 mg/dL were 122 and 61 days, respectively. In fact, no patients with PTH C7.08 pg/mL and only 1 patient with Ca-D1 C7.88 mg/dL required supplementation C6 months. These findings reconfirmed our initial hypothesis that both the severity of immediate hypoparathyroidism (as reflected by PTH-SC) and hypocalcemia (by Ca-D1) could predict the duration of needing supplementation. However, these findings were not surprising because those with low or near-normal PTH or Ca would be expected to have an earlier recovery of parathyroid function and a shorter duration of supplementation than those with very low or undetectable initial PTH or Ca. After all, most temporary hypoparathyroidism is probably a result of transient interruption of parathyroid blood supply, and so those with less compromised blood supply would be expected to recover sooner. This finding is in accord with those reported by other authors [12, 13] . In the second part of the analysis, we evaluated how sensitive and specific these two factors were in predicting supplementation \6 months (temporary hypoparathyroidism) and C6 months (permanent hypoparathyroidism). We found that both PTH-SC and Ca-D1 were very sensitive, although not very specific in predicting supplementation \6 and C6 months. None of the 24 patients with PTH-SC C7.08 pg/mL required supplementation C6 months regardless of the level of Ca-D1, and only 1 of the 23 patients with Ca-D1 C7.88 mg/dL required supplementation C6 months. However, it should be noted that the PPV was actually relatively low (30-40 %) (i.e., those with PTH-SC \7.08 pg/mL or Ca-D1 \7.88 mg/dL did not always require calcium and/or calcitriol supplementation C6 months). In fact, only 10 of 25 patients with PTH-SC \7.08 pg/mL required supplementation C6 months, and 9 of 26 patients with Ca-D1 \7.88 mg/dL required supplementation C6 months. The implication of these findings was that the majority (or at least two thirds) of patients would have normalization of parathyroid function to the extent that they would not need supplementation in the short to medium term. These findings were in accord with a study reporting that no patients with PTH-D1 C5 pg/mL required calcium and calcitriol supplementation lasting [1 month [14] . Interestingly, relative to using PTH-SC or Ca-D1 alone, combining both PTH-SC and Ca-D1 increased the PPV from 34.6-40.0 to 52.9 % and the AUC from 0.943-0.950 to 0.955. Although this finding might be seen as an improvement, the incremental clinical significance of this change remains uncertain. Perhaps other factors, such as parathyroid autotransplantation or the presence of ectopic parathyroid glands or rests, could potentially reduce the chance of longterm supplementation, although the former factor did not prove to be significant in the univariate analysis and so it was not evaluated [19] .
Clinical implications
Instead of having an intensive biweekly follow-up protocol for all patients taking supplementation on discharge (i.e., the blanket approach), our results could be extrapolated for stratifying patients requiring supplementation on discharge according to PTH-SC and Ca-D1. Because those with PTH [7.08 pg/mL and/or Ca-D1 [7. 88 mg/dL would have a significantly greater chance ([90 %) of being weaned from all supplementation within 6 months, a more intensive protocol would appear appropriate to minimize the duration of supplementation. In contrast, because those with PTH\7.08 pg/mL and/or Ca-D1\7.88 mg/dL would have a significantly lesser chance (50-66 %) of being successfully weaned off supplementation within 6 months, a less intensive follow-up (perhaps, a 1-2 monthly protocol) would be more appropriate and less troublesome for the patient.
Despite our findings, we would acknowledge some shortcomings of the present study in that when the duration of supplementation was calculated, for simplicity's sake, we did not make a clear distinction between patients who were weaned from calcium only and those who were weaned from both calcium and calcitriol. It is known that those taking both calcium and calcitriol have more severe hypoparathyroidism than those taking calcium alone and would have taken longer to be weaned from supplementation [12, 13] . The other shortcoming was the fact that some might think that our algorithm of weaning from supplementation was too slow, and that might have caused some patients actually taking supplements more than and/or for longer than it was necessary. For example, some might view that patients with adjusted Ca between 8.44 and 8.80 mg/dL probably could be weaned from supplementation rather than waiting until the adjusted Ca [8.80 mg/dL. Nevertheless, it was our policy that we would rather slightly ''overtreat'' biochemical hypocalcemia with supplementation than to cause transient symptomatic or biochemical hypocalcemia. We are worried that under-replacement my lead to deterioration in bone mineral density in the long term, although it remains unclear what the long-term consequences are. Also it would have been helpful if our data could be further supported by the follow-up or the latest postoperative PTH levels and to use these numbers to further correlate with duration of supplementation.
Conclusions
Our data show that both PTH-SC and Ca-D1 are independent factors for the duration of supplementation or chance of weaning from supplementation. Relative to patients with PTH-SC \7.08 pg/mL or Ca-D1 \7.88 mg/ dL, those with PTH-SC C7.08 pg/mL or Ca-D1 C7.88 mg/ dL had at least 2 times shorter duration of supplementation. Almost all patients with PTH-SC C7.08 pg/mL or Ca-D1 C7.88 mg/dL did not require supplementation beyond 6 months, whereas about one third of patients with PTH-SC \7.08 pg/mL or Ca-D1 \7.88 mg/dL required supplementation longer than 6 months.
